Åslaug Helland

12.2k citations
190 papers · 6.2k · 3 hit papers · h-index 40

Impact in

    • Cancer Genomics and Diagnostics
    • Cancer-related molecular mechanisms research
    • MicroRNA in disease regulation
  • Oncology top 1%
    • Cancer Immunotherapy and Biomarkers
    • Lung Cancer Research Studies

Papers in

Åslaug Helland

183 papers receiving 6.1k citations

Åslaug Helland's Hit Papers

Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study 2018 · 250 citations
2500+6+13Years since publication250500750

Peers

Åslaug Helland
Comparison fields: 5 of 133
  • Cancer Research 1.4k
  • Oncology 2.1k
  • Pulmonary and Respiratory Medicine 1.9k
  • Molecular Biology 2.4k
  • Immunology 688
Replace Young Kwang Chae with:
Young Kwang Chae United States
Ignacio Garrido‐Laguna United States
Mark N. Stein United States
Kazuko Sakai Japan
Paul G. Corn United States
Marius Ilié France
Jennifer J. Wheler United States
Allen Lee Cohn United States
Tae‐You Kim South Korea
Niels Reinmuth Germany
Åslaug Helland relative to Young Kwang Chae United States Young Kwang Chae's profile →
Citations per field
00.5×1.5×
Young Kwang Chae · 1×
Citations per year

Countries citing papers authored by Åslaug Helland

Since Specialization
Citations

This map shows the geographic impact of Åslaug Helland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Åslaug Helland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Åslaug Helland more than expected).

Fields of papers citing papers by Åslaug Helland

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Åslaug Helland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Åslaug Helland. The network helps show where Åslaug Helland may publish in the future.

Co-authors

The 25 scholars most cited alongside Åslaug Helland, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Åslaug Helland Line = papers co-authored together Åslaug Helland links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 190 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
Hit paper breakdown →
2017975
2
Gene Expression Programs in Response to Hypoxia: Cell Type Specificity and Prognostic Significance in Human Cancers
Hit paper breakdown →
2006501
3 2015256
4
Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study
Hit paper breakdown →
2018250
5 2019246
6 2009148
7 2014142
8 2014123
9 2011121
10 2011121
11 2018108
12 2005100
13 201492
14 201686
15 201879
16 201478
17 199366
18 199766
19 201565
20 201862

About Åslaug Helland

Åslaug Helland is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Cancer Research and Immunology, having authored 190 papers that have together received 6.2k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (39 papers), Cancer Genomics and Diagnostics (23 papers), Cancer Immunotherapy and Biomarkers (20 papers), Lung Cancer Diagnosis and Treatment (14 papers), Cancer-related molecular mechanisms research (12 papers), Epigenetics and DNA Methylation (11 papers), Cervical Cancer and HPV Research (9 papers) and Cancer-related Molecular Pathways (9 papers). The work is most often cited by research in Cancer Research (1.4k citations), Oncology (2.1k citations), Pulmonary and Respiratory Medicine (1.9k citations), Molecular Biology (2.4k citations) and Immunology (688 citations). Åslaug Helland has collaborated with scholars based in Norway, United States and Sweden. Frequent co-authors include Odd Terje Brustugun, Anne‐Lise Børresen‐Dale, Gunnar B. Kristensen, Julien Mazières, Anthony M. D’Amelio, Harry J.M. Groen, Benjamin Besse, Bijoyesh Mookerjee, Bruce E. Johnson and Egbert F. Smit. Their work appears in journals such as Annals of Oncology, Molecular Oncology, Journal of Thoracic Oncology, Acta Oncologica and International Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact